1. Home
  2. EOLS vs REPL Comparison

EOLS vs REPL Comparison

Compare EOLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.71

Market Cap

454.4M

Sector

Health Care

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$10.29

Market Cap

407.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOLS
REPL
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.4M
407.1M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
EOLS
REPL
Price
$5.71
$10.29
Analyst Decision
Strong Buy
Hold
Analyst Count
5
9
Target Price
$15.50
$5.67
AVG Volume (30 Days)
776.9K
3.2M
Earning Date
05-04-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
1.23
N/A
EPS
N/A
N/A
Revenue
$297,176,000.00
N/A
Revenue This Year
$13.27
N/A
Revenue Next Year
$17.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.61
N/A
52 Week Low
$3.86
$1.50
52 Week High
$10.20
$13.24

Technical Indicators

Market Signals
Indicator
EOLS
REPL
Relative Strength Index (RSI) 31.66 53.16
Support Level $4.02 $9.69
Resistance Level $7.16 $10.71
Average True Range (ATR) 0.33 0.77
MACD -0.17 -0.35
Stochastic Oscillator 11.95 36.77

Price Performance

Historical Comparison
EOLS
REPL

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: